Patents/Assignees

Revolution Medicines, Inc.

32 patents in portfolio

US12587381utility2026
Method and System for Monitoring and Controlling High Risk Substances
0 cites
US12565476utility2026
2,5-disubstituted 3-methyl Pyrazines and 2,5,6-trisubstituted 3-methyl Pyrazines as Allosteric SHP2 Inhibitors
0 cites
US12544448utility2026
C40-, C28-, and C-32-linked Rapamycin Analogs as Mtor Inhibitors
0 cites
US12539305utility2026
Methods of Treating Cancer with an Mtor Inhibitor
0 cites
US12528807utility2026
Solid Forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} Methanol, a SHP2 Inhibitor
0 cites
US12465643utility2025
Ras Inhibitors
0 cites
US12409225utility2025
Ras Inhibitors
0 cites
US12403196utility2025
Ras Inhibitors
0 cites
US12384750utility2025
Ras Inhibitors
0 cites
US12365688utility2025
Substituted Pyrazolopyrazines, Imidazopyrazines and [1,2,4]triazolopyrazines as Allosteric SHP2 Inhibitors
0 cites
US12280113utility2025
Ras Inhibitors
0 cites
US12258366utility2025
Bicyclic Heteroaryl Compounds and Uses Thereof
0 cites
US12252497utility2025
Ras Inhibitors
0 cites
US12202845utility2025
Ras Inhibitors
0 cites
US12187746utility2025
C26-linked Rapamycin Analogs as Mtor Inhibitors
0 cites
US12121522utility2024
Methods of Treating Cancer with an Mtor Inhibitor
0 cites
US12048749utility2024
C40-, C28-, and C-32-linked Rapamycin Analogs as Mtor Inhibitors
0 cites
US11987590utility2024
Compounds That Participate in Cooperative Binding and Uses Thereof
0 cites
US11952352utility2024
Ras Inhibitors
0 cites
US11739074utility2023
Ras Inhibitors
0 cites

Page 1 of 2Next →